×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ADIL – adial pharmaceuticals, inc (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ADIL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
05:59 am
adil
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Low
Report
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
11/14
08:42 am
adil
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder [Yahoo! Finance]
Low
Report
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder [Yahoo! Finance]
11/14
08:30 am
adil
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Medium
Report
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
11/14
07:35 am
adil
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock.
High
Report
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock.
11/13
08:30 am
adil
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
11/5
08:30 am
adil
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
Low
Report
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
10/23
09:00 am
adil
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Medium
Report
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
10/17
09:00 am
adil
Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment
High
Report
Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/18
04:01 pm
adil
Form 8-K ADIAL PHARMACEUTICALS, For: Nov 14
Neutral
Report
Form 8-K ADIAL PHARMACEUTICALS, For: Nov 14
11/18
04:01 pm
adil
Form 4 ADIAL PHARMACEUTICALS, For: Nov 16 Filed by: Shah Vinay
Neutral
Report
Form 4 ADIAL PHARMACEUTICALS, For: Nov 16 Filed by: Shah Vinay
11/18
04:00 pm
adil
Form 3 ADIAL PHARMACEUTICALS, For: Nov 16 Filed by: Shah Vinay
Neutral
Report
Form 3 ADIAL PHARMACEUTICALS, For: Nov 16 Filed by: Shah Vinay
11/14
03:44 pm
adil
Form SC 13G/A ADIAL PHARMACEUTICALS, Filed by: ARMISTICE CAPITAL, LLC
Medium
Report
Form SC 13G/A ADIAL PHARMACEUTICALS, Filed by: ARMISTICE CAPITAL, LLC
11/13
04:42 pm
adil
Form 10-Q ADIAL PHARMACEUTICALS, For: Sep 30
High
Report
Form 10-Q ADIAL PHARMACEUTICALS, For: Sep 30
11/12
04:13 pm
adil
Form 8-K ADIAL PHARMACEUTICALS, For: Nov 12
Low
Report
Form 8-K ADIAL PHARMACEUTICALS, For: Nov 12
11/5
08:45 am
adil
Form 8-K ADIAL PHARMACEUTICALS, For: Nov 01
Low
Report
Form 8-K ADIAL PHARMACEUTICALS, For: Nov 01
9/30
06:01 am
adil
Form ARS ADIAL PHARMACEUTICALS, For: Dec 31
Low
Report
Form ARS ADIAL PHARMACEUTICALS, For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/13
Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial
35.8%
4/16 Adial Pharmaceuticals Verifies Proprietary Genetic Test in Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial 26.1%
4/22 Form POS AM ADIAL PHARMACEUTICALS, 14.4%
3/26 Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder 13.0%
12/13 Form 4 ADIAL PHARMACEUTICALS, For: Dec 12 Filed by: Johnson Bankole A. 12.4%
6/6 Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization 6.8%
3/27 Form 4 ADIAL PHARMACEUTICALS, For: Mar 25 Filed by: Stilley William B. III 6.2%
2/19 Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria 6.0%
9/11 Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial 5.7%
6/13 Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder 5.6%
4/16 Adial Pharmaceuticals Verifies Proprietary Genetic Test in Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial 26.1%
4/22 Form POS AM ADIAL PHARMACEUTICALS, 14.4%
3/26 Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder 13.0%
12/13 Form 4 ADIAL PHARMACEUTICALS, For: Dec 12 Filed by: Johnson Bankole A. 12.4%
6/6 Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization 6.8%
3/27 Form 4 ADIAL PHARMACEUTICALS, For: Mar 25 Filed by: Stilley William B. III 6.2%
2/19 Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria 6.0%
9/11 Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial 5.7%
6/13 Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder 5.6%
TOP News Decliners
5/7
Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder
-13.5%
3/20 Form 10-K ADIAL PHARMACEUTICALS, For: Dec 31 -12.2%
2/14 Adial Pharmaceuticals CEO Selected as a Luncheon Keynote Speaker for the 2020 Wall Street Conference and Retreat -9.8%
3/30 Form 4 ADIAL PHARMACEUTICALS, For: Mar 27 Filed by: Newman James W. Jr. -8.2%
3/5 Form 4 ADIAL PHARMACEUTICALS, For: Mar 03 Filed by: Anderson J. Kermit -8.2%
6/9 Adial Pharmaceuticals Inc (NASDAQ: ADIL) was given a new $5.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -5.6%
6/19 Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare -5.6%
9/5 Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder -5.5%
9/11 Adial Pharma up 12% on confirmed product supply for late-stage study [Seeking Alpha] -5.4%
10/29 Adial Completes Final Packaging of AD04 for Shipment to Phase 3 Trial Clinical Sites -5.2%
3/20 Form 10-K ADIAL PHARMACEUTICALS, For: Dec 31 -12.2%
2/14 Adial Pharmaceuticals CEO Selected as a Luncheon Keynote Speaker for the 2020 Wall Street Conference and Retreat -9.8%
3/30 Form 4 ADIAL PHARMACEUTICALS, For: Mar 27 Filed by: Newman James W. Jr. -8.2%
3/5 Form 4 ADIAL PHARMACEUTICALS, For: Mar 03 Filed by: Anderson J. Kermit -8.2%
6/9 Adial Pharmaceuticals Inc (NASDAQ: ADIL) was given a new $5.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -5.6%
6/19 Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare -5.6%
9/5 Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder -5.5%
9/11 Adial Pharma up 12% on confirmed product supply for late-stage study [Seeking Alpha] -5.4%
10/29 Adial Completes Final Packaging of AD04 for Shipment to Phase 3 Trial Clinical Sites -5.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: